Romania Pharmaceuticals & Healthcare Q2 2019
The drug pricing environment, exemplified by the clawback tax, continues to pose considerable risks for drugmakers,limiting the Romanian pharmaceutical market's attractiveness. Reimbursement decisionmaking is slow, with a severe lack of publichealthcare finance. Having said this, pharmaceutical market growth remains on a robust trajectory, outperforming European peers.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook